Cargando…
Changes in systemic GDF15 across the adult lifespan and their impact on maximal muscle power: the Copenhagen Sarcopenia Study
BACKGROUND: Although growth differentiation factor 15 (GDF15) is known to increase with disease and is associated with low physical performance, the role of GDF15 in normal ageing is still not fully understood. Specifically, the influence of circulating GDF15 on impairments in maximal muscle power (...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718085/ https://www.ncbi.nlm.nih.gov/pubmed/34617415 http://dx.doi.org/10.1002/jcsm.12823 |
_version_ | 1784624648163426304 |
---|---|
author | Alcazar, Julian Frandsen, Ulrik Prokhorova, Tatyana Kamper, Rikke S. Haddock, Bryan Aagaard, Per Suetta, Charlotte |
author_facet | Alcazar, Julian Frandsen, Ulrik Prokhorova, Tatyana Kamper, Rikke S. Haddock, Bryan Aagaard, Per Suetta, Charlotte |
author_sort | Alcazar, Julian |
collection | PubMed |
description | BACKGROUND: Although growth differentiation factor 15 (GDF15) is known to increase with disease and is associated with low physical performance, the role of GDF15 in normal ageing is still not fully understood. Specifically, the influence of circulating GDF15 on impairments in maximal muscle power (a major contributor to functional limitations) and the underlying components has not been investigated. METHODS: Data from 1305 healthy women and men aged 20 to 93 years from The Copenhagen Sarcopenia Study were analysed. Circulating levels of GDF15 and markers of inflammation (tumor necrosis factor‐alpha, interleukin‐6, and high‐sensitivity C‐reactive protein) were measured by ELISA (R&D Systems) and multiplex bead‐based immunoassays (Bio‐Rad). Relative (normalized to body mass), allometric (normalized to height squared), and specific (normalized to leg muscle mass) muscle power were assessed by the Nottingham power rig [leg extension power (LEP)] and the 30 s sit‐to‐stand (STS) muscle power test. Total body fat, visceral fat, and leg lean mass were assessed by dual energy X‐ray absorptiometry. Leg skeletal muscle index was measured as leg lean mass normalized to body height squared. RESULTS: Systemic levels of GDF15 increased progressively as a function of age in women (1.1 ± 0.4 pg·mL(−1)·year(−1)) and men (3.3 ± 0.6 pg·mL(−1)·year(−1)) (both P < 0.05). Notably, GDF15 increased at a faster rate from the age of 65 years in women (11.5 ± 1.2 pg·mL(−1)·year(−1), P < 0.05) and 70 years in men (19.3 ± 2.3 pg·mL(−1)·year(−1), P < 0.05), resulting in higher GDF15 levels in men compared with women above the age of 65 years (P < 0.05). Independently of age and circulatory markers of inflammation, GDF15 was negatively correlated to relative STS power (P < 0.05) but not LEP, in both women and men. These findings were mainly explained by negative associations of GDF15 with specific STS power in women and men (both P < 0.05). CONCLUSIONS: A J‐shaped relationship between age and systemic GDF15 was observed, with men at older age showing steeper increases and elevated GDF15 levels compared with women. Importantly, circulating GDF15 was independently and negatively associated with relative STS power, supporting the potential role of GDF15 as a sensitive biomarker of frailty in older people. |
format | Online Article Text |
id | pubmed-8718085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87180852022-01-07 Changes in systemic GDF15 across the adult lifespan and their impact on maximal muscle power: the Copenhagen Sarcopenia Study Alcazar, Julian Frandsen, Ulrik Prokhorova, Tatyana Kamper, Rikke S. Haddock, Bryan Aagaard, Per Suetta, Charlotte J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: Although growth differentiation factor 15 (GDF15) is known to increase with disease and is associated with low physical performance, the role of GDF15 in normal ageing is still not fully understood. Specifically, the influence of circulating GDF15 on impairments in maximal muscle power (a major contributor to functional limitations) and the underlying components has not been investigated. METHODS: Data from 1305 healthy women and men aged 20 to 93 years from The Copenhagen Sarcopenia Study were analysed. Circulating levels of GDF15 and markers of inflammation (tumor necrosis factor‐alpha, interleukin‐6, and high‐sensitivity C‐reactive protein) were measured by ELISA (R&D Systems) and multiplex bead‐based immunoassays (Bio‐Rad). Relative (normalized to body mass), allometric (normalized to height squared), and specific (normalized to leg muscle mass) muscle power were assessed by the Nottingham power rig [leg extension power (LEP)] and the 30 s sit‐to‐stand (STS) muscle power test. Total body fat, visceral fat, and leg lean mass were assessed by dual energy X‐ray absorptiometry. Leg skeletal muscle index was measured as leg lean mass normalized to body height squared. RESULTS: Systemic levels of GDF15 increased progressively as a function of age in women (1.1 ± 0.4 pg·mL(−1)·year(−1)) and men (3.3 ± 0.6 pg·mL(−1)·year(−1)) (both P < 0.05). Notably, GDF15 increased at a faster rate from the age of 65 years in women (11.5 ± 1.2 pg·mL(−1)·year(−1), P < 0.05) and 70 years in men (19.3 ± 2.3 pg·mL(−1)·year(−1), P < 0.05), resulting in higher GDF15 levels in men compared with women above the age of 65 years (P < 0.05). Independently of age and circulatory markers of inflammation, GDF15 was negatively correlated to relative STS power (P < 0.05) but not LEP, in both women and men. These findings were mainly explained by negative associations of GDF15 with specific STS power in women and men (both P < 0.05). CONCLUSIONS: A J‐shaped relationship between age and systemic GDF15 was observed, with men at older age showing steeper increases and elevated GDF15 levels compared with women. Importantly, circulating GDF15 was independently and negatively associated with relative STS power, supporting the potential role of GDF15 as a sensitive biomarker of frailty in older people. John Wiley and Sons Inc. 2021-10-06 2021-12 /pmc/articles/PMC8718085/ /pubmed/34617415 http://dx.doi.org/10.1002/jcsm.12823 Text en © 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Alcazar, Julian Frandsen, Ulrik Prokhorova, Tatyana Kamper, Rikke S. Haddock, Bryan Aagaard, Per Suetta, Charlotte Changes in systemic GDF15 across the adult lifespan and their impact on maximal muscle power: the Copenhagen Sarcopenia Study |
title | Changes in systemic GDF15 across the adult lifespan and their impact on maximal muscle power: the Copenhagen Sarcopenia Study |
title_full | Changes in systemic GDF15 across the adult lifespan and their impact on maximal muscle power: the Copenhagen Sarcopenia Study |
title_fullStr | Changes in systemic GDF15 across the adult lifespan and their impact on maximal muscle power: the Copenhagen Sarcopenia Study |
title_full_unstemmed | Changes in systemic GDF15 across the adult lifespan and their impact on maximal muscle power: the Copenhagen Sarcopenia Study |
title_short | Changes in systemic GDF15 across the adult lifespan and their impact on maximal muscle power: the Copenhagen Sarcopenia Study |
title_sort | changes in systemic gdf15 across the adult lifespan and their impact on maximal muscle power: the copenhagen sarcopenia study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718085/ https://www.ncbi.nlm.nih.gov/pubmed/34617415 http://dx.doi.org/10.1002/jcsm.12823 |
work_keys_str_mv | AT alcazarjulian changesinsystemicgdf15acrosstheadultlifespanandtheirimpactonmaximalmusclepowerthecopenhagensarcopeniastudy AT frandsenulrik changesinsystemicgdf15acrosstheadultlifespanandtheirimpactonmaximalmusclepowerthecopenhagensarcopeniastudy AT prokhorovatatyana changesinsystemicgdf15acrosstheadultlifespanandtheirimpactonmaximalmusclepowerthecopenhagensarcopeniastudy AT kamperrikkes changesinsystemicgdf15acrosstheadultlifespanandtheirimpactonmaximalmusclepowerthecopenhagensarcopeniastudy AT haddockbryan changesinsystemicgdf15acrosstheadultlifespanandtheirimpactonmaximalmusclepowerthecopenhagensarcopeniastudy AT aagaardper changesinsystemicgdf15acrosstheadultlifespanandtheirimpactonmaximalmusclepowerthecopenhagensarcopeniastudy AT suettacharlotte changesinsystemicgdf15acrosstheadultlifespanandtheirimpactonmaximalmusclepowerthecopenhagensarcopeniastudy |